AAAAAA

   
Results: 1-15 |
Results: 15
Immunologic approaches to the management of pancreatic cancer
Authors: Laheru, D Biedrzycki, B Jaffee, EM
Citation: D. Laheru et al., Immunologic approaches to the management of pancreatic cancer, CANCER J, 7(4), 2001, pp. 324-337
Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors
Authors: Wesseling, JG Bosma, PJ Krasnykh, V Kashentseva, EA Blackwell, JL Reynolds, PN Li, H Parameshwar, M Vickers, SM Jaffee, EM Huibregtse, K Curiel, DT Dmitriev, I
Citation: Jg. Wesseling et al., Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors, GENE THER, 8(13), 2001, pp. 969-976
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immuneactivation
Authors: Jaffee, EM Hruban, RH Biedrzycki, B Laheru, D Schepers, K Sauter, PR Goemann, M Coleman, J Grochow, L Donehower, RC Lillemoe, KD O'Reilly, S Abrams, RA Pardoll, DM Cameron, JL Yeo, CJ
Citation: Em. Jaffee et al., Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immuneactivation, J CL ONCOL, 19(1), 2001, pp. 145-156
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immuneresponse of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice
Authors: Machiels, JPH Reilly, RT Emens, LA Ercolini, A Lei, RY Weintraub, D Okoye, FI Jaffee, EM
Citation: Jph. Machiels et al., Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immuneresponse of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice, CANCER RES, 61(9), 2001, pp. 3689-3697
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors
Authors: Reilly, RT Machiels, JPH Emens, LA Ercolini, AM Okoye, FI Lei, RY Weintraub, D Jaffee, EM
Citation: Rt. Reilly et al., The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors, CANCER RES, 61(3), 2001, pp. 880-883
Discovery of new markers of cancer through serial analysis of gene expression: Prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma
Authors: Argani, P Rosty, C Reiter, RE Wilentz, RE Murugesan, SR Leach, SD Ryu, BW Skinner, HG Goggins, M Jaffee, EM Yeo, CJ Cameron, JL Kern, SE Hruban, RH
Citation: P. Argani et al., Discovery of new markers of cancer through serial analysis of gene expression: Prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma, CANCER RES, 61(11), 2001, pp. 4320-4324
Progress toward cancer vaccines
Authors: Jaffee, EM
Citation: Em. Jaffee, Progress toward cancer vaccines, HOSP PRACT, 35(12), 2000, pp. 49
Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system
Authors: Ewend, MG Thompson, RC Anderson, R Sills, AK Staveley-O'Carroll, K Tyler, BM Hanes, J Brat, D Thomas, M Jaffee, EM Pardoll, DM Brem, H
Citation: Mg. Ewend et al., Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system, J IMMUNOTH, 23(4), 2000, pp. 438-448
Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex
Authors: Slansky, JE Rattis, FM Boyd, LF Fahmy, T Jaffee, EM Schneck, JP Margulies, DH Pardoll, DM
Citation: Je. Slansky et al., Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex, IMMUNITY, 13(4), 2000, pp. 529-538
Potential role of tumor vaccines in GI malignancies
Authors: Laheru, DA Jaffee, EM
Citation: Da. Laheru et Em. Jaffee, Potential role of tumor vaccines in GI malignancies, ONCOLOGY-NY, 14(2), 2000, pp. 245-256
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: Acceptable toxicity and suggestion of improved 1-year disease-free survival
Authors: Chakravarthy, A Abrams, RA Yeo, CJ Korman, LT Donehower, RC Hruban, RH Zahurek, ML Grochow, LB O'Reilly, S Hurwitz, H Jaffee, EM Lillemoe, KD Cameron, JL
Citation: A. Chakravarthy et al., Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: Acceptable toxicity and suggestion of improved 1-year disease-free survival, INT J RAD O, 48(4), 2000, pp. 1089-1096
How much longer will tumour cells fool the immune system?
Authors: Ferrone, S Finerty, JF Jaffee, EM Nabel, GJ
Citation: S. Ferrone et al., How much longer will tumour cells fool the immune system?, IMMUNOL TOD, 21(2), 2000, pp. 70-72
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice
Authors: Reilly, RT Gottlieb, MBC Ercolini, AM Machiels, JPH Kane, CE Okoye, FI Muller, WJ Dixon, KH Jaffee, EM
Citation: Rt. Reilly et al., HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice, CANCER RES, 60(13), 2000, pp. 3569-3576
Cancer vaccines
Authors: Greten, TF Jaffee, EM
Citation: Tf. Greten et Em. Jaffee, Cancer vaccines, J CL ONCOL, 17(3), 1999, pp. 1047-1060
T-cell adoptive immunotherapy of metastatic renal cell carcinoma - Editorial comment
Authors: Jaffee, EM
Citation: Em. Jaffee, T-cell adoptive immunotherapy of metastatic renal cell carcinoma - Editorial comment, UROLOGY, 54(4), 1999, pp. 623-624
Risultati: 1-15 |